<DOC>
	<DOC>NCT00186680</DOC>
	<brief_summary>Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.</brief_summary>
	<brief_title>CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant</brief_title>
	<detailed_description>Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide &amp; Cisplatin for Stage IV Breast Cancer &amp; Limited Prior Treatment</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>stage IV breast cancer primary breast cancer does not express CD34+ adequate organ function no evidence of active infection chemotherapy within 4 weeks CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>